


CLAIMS


1. A compound having the formula



and pharmaceutically acceptable salts, solvates, and crystalline forms thereof.

2. A process for the preparation of a compound according to claim 1, characterized by


a) converting a compound of the formula II




wherein A is a chiral auxiliary group or the group  $-OR^P$ , wherein  $R^P$  is a protective group,  
or

b) reacting a compound of the formula III

35



with a compound of the formula IV




5

in which formulas A is -OH, a chiral auxiliary group or the group -OR<sup>P</sup>, wherein R<sup>P</sup> is a protective group, X is -OH or a leaving group and Q is H, whereafter, if necessary, hydrolysing the obtained compound, or

10

c) diastereoisomerically separating a compound of the formula V




15

wherein Q is -CH<sub>2</sub>CH<sub>2</sub>Ph-4-OSO<sub>2</sub>CH<sub>3</sub> and A is a chiral auxiliary group, whereafter hydrolysing the obtained compound, or


d) enantiomerically separating a compound of the formula V

20



wherein Q is  $-\text{CH}_2\text{CH}_2\text{Ph}-4\text{-OSO}_2\text{CH}_3$  and A is  $-\text{OH}$  or  $-\text{OR}^{\text{P}}$ , wherein  $\text{R}^{\text{P}}$  is a protective  
 5 group, whereafter, if necessary hydrolysing the obtained compound, or


e) asymmetrically reducing a compound of the formula VII



10


wherein Q is  $-\text{CH}_2\text{CH}_2\text{Ph}-4\text{-OSO}_2\text{CH}_3$  and A is  $-\text{OH}$ , a chiral auxiliary group or the group  
 $-\text{OR}^{\text{P}}$ , wherein  $\text{R}^{\text{P}}$  is a protective group, whereafter, if necessary, hydrolysing the obtained  
 compound, or

15 f) alkylating a compound of the formula XII




wherein Q is  $-\text{CH}_2\text{CH}_2\text{Ph}-4\text{-OSO}_2\text{CH}_3$  and A is  $-\text{OH}$ , a chiral auxiliary group or the group  
 20  $-\text{OR}^{\text{P}}$ , wherein  $\text{R}^{\text{P}}$  is a protective group, whereafter, if necessary, hydrolysing the obtained  
 compound, or

g) reacting a compound of the formula XV




5 with a compound of the formula IX



10 in which formulas X is a leaving group, Q is  $-\text{CH}_2\text{CH}_2\text{Ph}-4\text{-OSO}_2\text{CH}_3$  and A is a chiral auxiliary group used to induce chirality in the product whereafter, hydrolysing the obtained compound, or


h) resolving a racemate of the formula I<sup>rac</sup>



15 whereafter, if desired, the compound obtained according to any of methods a)-h) is converted to a pharmaceutically acceptable salt, and/or a solvate such as a hydrate thereof.

20 3. A compound of the formula IV

38



IV

wherein Q is hydrogen and A is -OH, a chiral auxiliary group or the group -OR<sup>P</sup>, wherein R<sup>P</sup> is a protective group.

5

4. A compound according to claim 3, wherein in formula IV A is -OH or alkoxy having 1 to 3 carbon atoms.

5. A compound according to claim 1 for use in therapy.

10

6. A pharmaceutical formulation containing a compound according to claim 1 as active ingredient optionally together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

15

7. The use of a compound according to claim 1 in the manufacture of a medicament for the prophylaxis and/or treatment of clinical conditions associated with insulin resistance.

8. A method for the prophylaxis and/or treatment of clinical conditions associated with insulin resistance wherein a therapeutically active amount of a compound according to claim 1 is administered to a mammal in the need of such prophylaxis and/or treatment.

20

9. A method according to claim 8 wherein the prophylaxis and/or treatment of clinical conditions associated with insulin resistance is the prophylaxis and/or treatment of dyslipidaemia in such conditions.

25

10. A method according to claim 8 wherein the prophylaxis and/or treatment of clinical conditions associated with insulin resistance is the prophylaxis and/or treatment of hyperglycaemia in non insulin dependent diabetes mellitus.
- 5 11. A pharmaceutical formulation for use in the prophylaxis and/or treatment of clinical conditions associated with insulin resistance wherein the active ingredient is a compound according to claim 1.